TCT 2019 | EURO-CTO: Results at 3 Years of CTO Recanalization vs. Optimal Medical Treatment

Courtesy of SBHCI.

Between 16 and 18% of coronary artery lesions in patients with chronic stable CAD are chronic total occlusions (CTO). CTO revascularization could benefit symptomatic patients, but it remains unclear whether such complex procedure is safe in the long run, given the study outcomes on PCI in CAD so far. 

Highlights TCT 2019

This study presented at the scientific sessions of TCT 2019 randomized multivessel patients with at least one CTO to DES stenting on severe lesions and further functional ischemia assessment vs. optimal medical treatment. 

The study included 407 patients from 26 centers and 8 countries to recanalization plus optimal medical treatment (OMT) (n=259) vs OMT alone (n=137). Both successful CTO intervention + OMT and OMT alone patients were assessed with a functional test at 12 and 36 months. 

There were no differences in hard end points (infarction or death) between the groups, but patients with successful recanalization did present better quality of life, less frequent angina, better functional class and less physical limitation. 

18.2% of OMT patients and 7.3% of PCI + OMT patients needed new ischemia driven revascularization after 3 years. 

Conclusion

This study is the first to show a benefit of PCI over OMT in symptomatic CTO patients. There was significant event reduction in the PCI group basically driven by symptom improvement and better rate of re

Courtesy of SBHCI.

Link to the SBHCI publication HERE

euro-cto

Original Title: EURO-CTO: 3-Year Outcomes From a Randomized Trial of PCI vs. Medical Therapy in Patients With Chronic Total Coronary Occlusions.

Author of the Original Article: Gerald S. Werner.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....